Platelet-rich plasma (PRP), an autologous concentrate of platelets and bioactive molecules, has emerged as a promising regenerative therapy in cardiovascular medicine. The potential of PRP extends beyond hemostasis to include myocardial repair, angiogenesis, and immunomodulation. This review explores the biological mechanisms of PRP, its clinical applications in ischemic heart disease, peripheral artery disease, and inflammatory cardiopathies, and addresses challenges in standardization and translation. PRP exerts therapeutic effects through three primary mechanisms: promoting angiogenesis by stimulating endothelial cell proliferation and migration, exerting anti-inflammatory and immunomodulatory effects by balancing cytokine release, and enhancing myocardial repair and functional recovery by activating resident cardiac progenitor cells. Despite the promise of PRP, challenges such as variability in PRP composition due to differences in preparation methods and safety concerns remain. To overcome these barriers, precision engineering and cross-disciplinary integration are crucial. Innovations such as nanotechnology-driven targeted delivery systems and clustered regularly interspaced short palindromic repeats (CRISPR)-edited exosomes offer mechanism-specific interventions. Artificial intelligence (AI)-driven approaches utilizing single-cell RNA sequencing data can enable personalized treatment strategies, while closed-loop systems minimize batch-to-batch variability. Collaborative efforts between clinicians, engineers, and regulators are essential to establish global standards for exosome characterization. PRP-based therapies hold immense promise for revolutionizing cardiovascular regenerative medicine by modulating angiogenesis, inflammation, and myocardial repair. By embracing these advanced technologies and interdisciplinary approaches, PRP can transition from an empirical treatment to a data-driven, mechanism-specific intervention, ultimately redefining the future of cardiovascular care.
18 August 2025 in American Journal of Case Reports
BACKGROUND Fever, defined as an elevation in body temperature beyond the normal range, presents a diagnostic and therapeutic challenge due to its multifactorial etiology. The purpose of publishing this case report is to highlight the diagnostic challenges posed by recurrent fever and emphasize the importance of a systematic and comprehensive approach, while also proposing a novel diagnostic algorithm to improve management and minimize unnecessary antibiotic use. CASE REPORT We report a case of a 26-year-old woman with recurrent fever, headache, and myalgia, unresponsive to initial antiviral and antibiotic therapies. Despite negative viral and bacterial tests, various medications failed to produce significant clinical improvement. Elevated liver function tests and procalcitonin levels suggested an atypical infection. Administration of doxycycline led to symptom alleviation; however, the diagnosis remains unconfirmed without definitive testing. This case underscores the importance of adopting a systematic and comprehensive diagnostic approach for unclear illnesses. While empirical treatment may be necessitated, caution is urged to avoid unjustified use of antibiotics and medications without a clear diagnosis. Balancing empirical therapy with thorough evaluation is crucial for effective fever management, minimizing the risks of misdiagnosis or inappropriate treatment. We propose a novel diagnostic algorithm integrating rapid molecular diagnostics and advanced imaging to minimize unnecessary antibiotic use and improve patient outcomes. CONCLUSIONS The management of recurrent febrile illnesses requires a balanced approach, integrating empirical treatment with comprehensive diagnostic evaluation. Our proposed diagnostic algorithm offers a structured pathway to improve patient outcomes and reduce unnecessary antibiotic use. Further research is essential to validate this approach and establish standardized protocols for fever management.